How to cite this article: Halliday AJ, Campbell TE, Razal JM, McLean KJ, Nelson TS, Cook MJ, Wallace GG. 2012. In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing Levetiracetam, for the treatment of epilepsy. J Biomed Mater Res Part A 2012:100A:424-431.
In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy †
Article first published online: 21 NOV 2011
Copyright © 2011 Wiley Periodicals, Inc.
Journal of Biomedical Materials Research Part A
Volume 100A, Issue 2, pages 424–431, February 2012
How to Cite
Halliday, A. J., Campbell, T. E., Razal, J. M., McLean, K. J., Nelson, T. S., Cook, M. J. and Wallace, G. G. (2012), In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy . J. Biomed. Mater. Res., 100A: 424–431. doi: 10.1002/jbm.a.33208
- Issue published online: 22 DEC 2011
- Article first published online: 21 NOV 2011
- Manuscript Accepted: 10 JUN 2011
- Manuscript Revised: 3 JUN 2011
- Manuscript Received: 17 JAN 2011
- Victorian Government through its Science Technology and Innovation Initiative from the Department of Industry, Innovation, and Regional Development; ARC Federation Fellowship (to G.G.W.); Australian Research Council for the APD Fellowship (to J.M.R.)
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, and is highly resistant to medication with up to 40% of patients continuing to experience seizures whilst taking oral antiepileptic drugs. Recent research suggests that this may be due to abnormalities in the blood–brain barrier, which prevent the passage of therapeutic substances into the brain. We sought to develop a drug delivery material that could be implanted within the brain at the origin of the seizures to release antiepileptic drugs locally and avoid the blood brain barrier. We produced poly-lactide-co-glycolide drop-cast films and wet-spun fibers loaded with the novel antiepileptic drug Levetiracetam, and investigated their morphology, in vitro drug release characteristics, and brain biocompatibility in adult rats. The best performing structures released Levetiracetam constantly for at least 5 months in vitro, and were found to be highly brain biocompatible following month-long implantations in the motor cortex of adult rats. These results demonstrate the potential of polymer-based drug delivery devices in the treatment of epilepsy and warrant their investigation in animal models of focal epilepsy. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.